long intergenic non-protein coding RNA 2285Genealiases: []
Q-omics provides the consensus-scored LINC02285 profile across patient tissues and cancer cell-line models. LINC02285 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC02285 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC02285 RNA expression shows 15,122 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where LINC02285 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02285 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02285 survival associations across molecular data types. LINC02285 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02285 RNA expression–survival associations across cancer types. High LINC02285 expression shows unfavorable associations in LGG, but favorable associations in SKCM, CESC, HNSC, LUAD and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC02285 RNA expression.
This table summarizes LINC02285 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02285. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02285 shows lower tumor expression in LUAD, LUSC and BLCA and higher tumor expression in KIRC, THCA and STAD. The KIRC box plot shows higher LINC02285 RNA expression in tumor versus normal tissue (log2 FC = +0.812, t-test p < 0.001).
This table shows molecular features associated with LINC02285 in patient tissues and cancer cell lines. In patient samples, LINC02285 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
